FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response	: 0.5						

Held by

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] <u>VITA NICHOLAS</u>		son*	2. Issuer Name and Ticker or Trading Symbol Cannabist Co Holdings Inc. [CBSTF]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
				X	Director	10% Owner Other (specify below) Officer				
(Last) (First) (Middle) C/O THE CANNABIST COMPANY HOLDINGS INC. 680 FIFTH AVENUE, 24TH FLOOR		()	3. Date of Earliest Transaction (Month/Day/Year) 12/04/2023	X	Officer (give title below) Chief Executive					
		OOR	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicab Line) X Form filed by One Reporting Person 						
(Street) NEW YORK	NY	10019			Form filed by More tha Person	n One Reporting				
			Rule 10b5-1(c) Transaction Indication							
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature Execution Date, Transaction Securities Beneficially Form: Direct Date of Indirect (Month/Day/Year) if any Code (Instr (D) or Indirect Beneficial (Month/Day/Year) 8) Owned Following Reported (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Price v Code Amount (Instr. 3 and 4) Held by Vita **Common Shares** 12/04/2023 150,000 D **\$0.3532**⁽¹⁾ 20,777,075 S I Holdings LLC⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Common Shares								618,950	D	
Common Shares	12/05/2023		S		200,000	D	\$0.3544 ⁽²⁾	20,577,075	Ι	Vita Holdings LLC ⁽³⁾

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	of Expiration Date Derivative (Month/Day/Year) Securities Acquired (A) or		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales price reported above was converted from the Canadian weighted average price of 0.478333 using an exchange rate of C\$1.3541 = US\$1.00. These shares were sold in multiple transactions at prices ranging from C\$0.47 to 0.475, inclusive. The Reporting Person undertakes to provide to The Cannabist Company Holdings Inc., any security holder of The Cannabist Company Holdings Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The sale price reported above was converted from the Canadian weighted average price of C\$0.48125 using an exchange rate of C\$1.3579 = US\$1.00. These shares were sold in multiple transactions at price ranging from C\$0.48 to \$0.485, inclusive. The Reporting Person undertakes to provide to The Cannabist Company Holdings Inc., any security holder of The Cannabist Company Holdings Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. 3. Shares sold by third-party financial institution in partial satisfaction of debt obligation. Funding was primarily used for pediatric medical research for orphan and ultra rare illnesses, tax payments,

5. Shares sold by undeparty mancial institution in partial satisfaction of debt obligation. Funding was primarily used for pediatric medical research for orphan and ultra rare illnesses, tax payments, education and philanthropic purposes.



12/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See